TABLE 3.
Liver Transplant Recipient Characteristics
| SIPAT Score† |
||||
|---|---|---|---|---|
| Characteristic | Total (n = 384) | <21 (N = 285), 74% | ≥21 (n = 99), 26% | P Value |
|
| ||||
| Sex | 0.21 | |||
| Female | 108 (28) | 85 (30) | 23 (23) | |
| Male | 276 (72) | 200 (70) | 76 (77) | |
| Age, years | 59 (52–64) | 59 (52–64) | 57 (52–63) | 0.07 |
| Race/ethnicity | 0.31 | |||
| White/Caucasian | 289 (75) | 214 (75) | 75 (76) | |
| Black/African American | 54 (14) | 36 (13) | 18 (18) | |
| Asian | 16 (4) | 14 (5) | 2 (2) | |
| Hispanic/Latinx | 22 (6) | 18 (6) | 4 (4) | |
| Other | 3 (1) | 3 (1) | 0 | |
| Primary insurance | 0.16 | |||
| Private | 273 (71) | 207 (73) | 66 (67) | |
| Medicaid | 10 (3) | 5 (2) | 5 (5) | |
| Medicare | 101 (26) | 73 (26) | 28 (28) | |
| Education‡ | 0.27 | |||
| Less than high school | 10 (3) | 7 (3) | 3 (3) | |
| High school/GED | 154 (41) | 106 (38) | 48 (49) | |
| Some college/technical school | 83 (22) | 67 (24) | 16 (16) | |
| Associate’s/bachelor’s degree | 87 (23) | 65 (23) | 22 (22) | |
| Post–college graduate degree | 46 (12) | 37 (13) | 9 (9) | |
| CHS | ||||
| Health outcomes | 13 (5–34) | 11 (5–32) | 15 (5–34) | 0.34 |
| Health factors | 12 (3–26) | 11 (3–24) | 12 (3–33) | 0.29 |
| Karnofsky Performance Status | 0.68 | |||
| 10%−40% | 126 (33) | 90 (32) | 36 (36) | |
| 50%−70% | 161 (42) | 122 (43) | 39 (39) | |
| 80%−100% | 97 (25) | 73 (26) | 24 (24) | |
| MELD-Na at transplant | 0.38 | |||
| <25 | 242 (63) | 184 (65) | 58 (59) | |
| 25–34 | 91 (24) | 67 (24) | 24 (24) | |
| >35 | 51 (13) | 34 (12) | 17 (17) | |
| Evaluation MELD-Na§ | 0.002* | |||
| <25 | 273 (67) | 203 (71) | 52 (53) | |
| 25–34 | 111 (27) | 71 (25) | 36 (37) | |
| >35 | 22 (5) | 11 (4) | 10 (10) | |
| Liver disease etiology | <0.001* | |||
| HCV | 137 (36) | 90 (32) | 47 (47) | |
| ALD | 95 (25) | 56 (20) | 39 (39) | |
| HBV | 14 (4) | 12 (4) | 2 (2) | |
| NASH/cryptogenic | 58 (15) | 54 (19) | 4 (4) | |
| PSC | 30 (8) | 29 (10) | 1 (1) | |
| Autoimmune | 14 (4) | 12 (4) | 2 (2) | |
| PBC | 17 (4) | 16 (6) | 1 (1) | |
| Other | 17 (5) | 16 (6) | 3 (3) | |
| Simultaneous kidney transplant | 18 (5) | 13 (5) | 5 (5) | 0.84 |
| Body mass index, kg/m2 | 27 (24–31) | 26 (23–31) | 28 (25–31) | 0.14 |
| Patient deaths | 32 (8) | 23 (8) | 9 (9) | 0.75 |
| Allograft rejection | 42 (11) | 30 (11) | 12 (12) | 0.66 |
| Tacrolimus CoV¶ | 0.38 (0.30–0.50) | 0.36 (0.29–0.46) | 0.46 (0.35–0.57) | <0.001* |
| ≥0.45 | 134 (36) | 81 (30) | 53 (54) | <0.001* |
NOTE: Data are provided as n (%) or median (interquartile range).
*
P < 0.05.
†
A cutoff score of 21 chosen to distinguish good/excellent candidates (<21) from minimally acceptable to high-risk candidates (≥21).
‡
A total of 4 missing values.
§
A total of 1 missing value.
¶
n = 371. Higher tacrolimus CoV indicates higher tacrolimus level variability and serves as a marker of possible medication nonadherence. We only included outpatient tacrolimus values >3 months after LT.